Valneva SE (VALN) Operating Income (2021 - 2026)
Valneva SE (VALN) posted Operating Income of -$27.7 million for Q1 2026, up 15.23% sequentially from -$32.7 million in Q4 2025, and down 342.51% YoY from $11.4 million in Q1 2025.
Valneva SE (VALN) Operating Income (2021 - 2026) Analysis & Trends
Valneva SE has reported Operating Income for 6 years, with the latest figure at -$27.7 million in Q1 2026.
- Quarterly Operating Income fell 342.51% year-over-year to -$27.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$116.2 million (down 77.46% YoY) and the FY2025 annual result came in at -$95.5 million, down 762.08% from the prior year.
- Operating Income grew to -$27.7 million in Q1 2026 per VALN's latest filing, from -$32.7 million in the prior quarter.
- Over five years, Operating Income peaked at $94.1 million in Q3 2022 and troughed at -$140.8 million in Q2 2022.
- A 5-year average of -$18.9 million and a median of -$22.3 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2024 and 2026: Operating Income surged 516.53% in 2024, then sank 342.51% in 2026.
- Over 5 years, Operating Income stood at -$57.5 million in 2022, then jumped by 53.39% to -$26.8 million in 2023, then grew by 16.72% to -$22.3 million in 2024, then slumped by 46.65% to -$32.7 million in 2025, then increased by 15.23% to -$27.7 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$27.7 million, -$32.7 million, and -$43.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | -30.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.44 Mn |
| Mar 31, 2026 | -27.74 Mn |
| Dec 31, 2025 | -32.73 Mn |
| Sep 30, 2025 | -43.39 Mn |
| Jun 30, 2025 | -12.30 Mn |
| Mar 31, 2025 | -6.27 Mn |
| Dec 31, 2024 | -22.32 Mn |
| Sep 30, 2024 | -13.67 Mn |
| Jun 30, 2024 | -23.20 Mn |
| Mar 31, 2024 | 74.10 Mn |
| Dec 31, 2023 | -26.80 Mn |
| Sep 30, 2023 | -24.18 Mn |
| Jun 30, 2023 | -20.03 Mn |
| Mar 31, 2023 | -17.79 Mn |
| Dec 31, 2022 | -57.49 Mn |
| Sep 30, 2022 | 94.09 Mn |
| Jun 30, 2022 | -140.84 Mn |
| Mar 31, 2022 | -20.68 Mn |
| Dec 31, 2021 | 201.58 Mn |
| Sep 30, 2021 | -178.58 Mn |